Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study
Jonathan Corren,1 Martin Karpefors,2 Åsa Hellqvist,3 Jane R Parnes,4 Gene Colice5 1Departments of Medicine and Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; 2Data Science and AI, AstraZeneca, Gothenburg, Sweden; 3Biometrics, Late-Stage Develop...
Main Authors: | Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-01-01
|
Series: | Journal of Asthma and Allergy |
Subjects: | |
Online Access: | https://www.dovepress.com/tezepelumab-reduces-exacerbations-across-all-seasons-in-patients-with--peer-reviewed-article-JAA |
Similar Items
-
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study
by: Emson C, et al.
Published: (2021-02-01) -
Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
by: Andrew Menzies-Gow, et al.
Published: (2020-10-01) -
TSLP‐targeting therapy: Beyond allergy?
by: Risa Ebina‐Shibuya, et al.
Published: (2023-05-01) -
Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab
by: Shih-Lung Cheng
Published: (2021-07-01) -
Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR
by: Laidlaw TM, et al.
Published: (2023-09-01)